发明名称 HUMAN IMMUNODEFICIENCY VIRUS ENTRY INHIBITOR ASSAY
摘要 The present invention is a method for evaluating the ability of a compound to prevent the Human Immunodeficiency Virus ("HIV") from entering into a T cell. The method involves fusing a first cell line that mimics HIV viral particles by expressing a gp120-gp41 complex on the cell surface and that contains a Tat protein in the cytoplasm with a second cell line that mimics T cells by expressing CD4 and its co-receptors on the cell surface and that contains a Tat-inducible reporter gene expression cassette in the nucleus. The cell lines are fused alone or in the presence of a potential HIV entry inhibitor and the amount of beta-galactosidase produced by the fused cells is determined. Compounds that reduce the amount of 0-galactosidase produced by the fused cells have interfered with the interaction of the gp120-gp41 complex and CD4 and its co-receptors and are therefore deemed be HIV entry inhibitors.
申请公布号 US2007092939(A1) 申请公布日期 2007.04.26
申请号 US20040580703 申请日期 2004.11.24
申请人 ZOU LINGLONG 发明人 ZOU LINGLONG
分类号 C12Q1/68;C07K;C12P21/06;C12Q1/70;G01N33/50;G01N33/53;G01N33/536;G01N33/569;G01N33/574 主分类号 C12Q1/68
代理机构 代理人
主权项
地址